- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01594918
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients With Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
This is a Phase I, open label, dose-finding, multicenter clinical trial to establish the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of cabazitaxel (25 mg/m2 IV q21 days) in combination with mitoxantrone (4-12 mg/m2 IV q21 days) and prednisone (5mg orally BID) in patients with metastatic CRPC who have not undergone prior chemotherapy for metastatic disease.
Up to five cohorts will be enrolled to determine the MTD and DLT profile of this combination. An accelerated titration design method is being used in order to minimize the number of patients exposed to subtherapeutic doses of mitoxantrone.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Arizona
-
Scottsdale, Arizona, Stany Zjednoczone, 85259
- Mayo Clinic
-
-
California
-
San Francisco, California, Stany Zjednoczone, 94115
- UCSF Comprehensive Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Vanderbilt-Ingram Cancer Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
1. Histologically confirmed adenocarcinoma of the prostate.
2. Progressive metastatic prostate cancer (positive bone scan or measurable disease) despite castrate levels of testosterone (either from orchiectomy or LHRH agonist therapy).
3. Patients may have either non-measurable disease OR measurable disease
4. All patients must have a PSA ≥ 2 ng/mL.
5. Progressive disease based on any one of the following:
- transaxial imaging
- a rise in PSA
radionuclide bone scan
Patients whose sole manifestation of progression is an increase in disease-related symptoms are not eligible.
- For patients with measurable disease, progression will be defined by the RECIST criteria.
- For patients with non-measurable disease, a positive bone scan and elevated PSA will be required. PSA evidence for progressive prostate cancer during or after first-line chemotherapy consists of a PSA level of at least 2 ng/ml which has risen on at least 2 successive occasions, at least one week apart. If the confirmatory PSA (#3) value is less (i.e., #3b) than the screening PSA (#2) value, then an additional test for rising PSA (#4) will be required to document progression for the purposes of eligibility.
Radionuclide bone scan: new metastatic lesions
6. Testosterone < 50 ng/dL. Patients must continue primary androgen deprivation with an LHRH analogue if they have not undergone orchiectomy.
7. ECOG Performance Status 0 -2.
8. Required Laboratory values:
- Creatinine < 1.5 x upper limits of normal (ULN). If Cr. > 1.5 x ULN, then calculated creatinine clearance > 40cc/min.
- ALT and AST within normal limits
- Absolute neutrophil count > 2,000/mm3
- Platelets > 100,000/ mm3
- Hemoglobin > 8.0 gm/dL
Total bilirubin within normal limits
9. Ejection fraction by MUGA scan or echocardiogram ≥ lower limit of institutional normal.
10. Patients receiving hormonal therapy (i.e. any dose of megestrol acetate (Megace), Proscar (finasteride), any herbal product known to decrease PSA levels (e.g., Saw Palmetto and PC-SPES) other than LHRH agonist/antagonist or a stable dose of corticosteroid from a prior chemotherapy regimen must discontinue the agent for at least 4 weeks prior to enrollment. Progressive disease must be documented after discontinuation of the hormonal therapy.
11. No other systemic therapies for prostate cancer within 28 days prior to initiation of this protocol.
12. Prior radiation therapy completed ≥ 4 weeks prior to enrollment.
13. No history of radiopharmaceuticals (strontium, samarium) for prostate cancer treatment.
14. Patients must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy. Should a patient's sexual partner become pregnant or suspect she is pregnant while the patient is participating in this study, he should inform the treating physician immediately.
15. Life expectancy > 12 weeks.
16. Age ≥ 18 years
17. Inclusion of Minorities: Men and members of all ethnic groups are eligible for this trial.
Exclusion Criteria:
- Patients with significant cardiovascular disease including congestive heart failure (NYHA class III or IV), active angina pectoris or myocardial infarction within 6 months.
- Patients with serious intercurrent infections, or nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this therapy.
- Patients with psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with pre-existing neuropathy greater than CTCAE Grade 1 (motor or sensory).
- Patients with known prior severe hypersensitivity reactions to cabazitaxel or other agents containing polysorbate 80.
- Patients with known active brain metastases are excluded because of their poor prognosis. Head CT is NOT routinely required prior to enrollment. Patients with treated, asymptomatic brain metastasis will be eligible for enrollment.
- Patients with a "currently active" second malignancy other than non-melanoma skin cancer are excluded. [Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse.]
- Concurrent use of moderate to strong CYP3A4 inhibitors is not allowed.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Cabazitaxel, Mitoxantrone, Prednisone
|
25 mg/m2 or 20 mg/m2, IV, once every 21 days
Inne nazwy:
4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
Inne nazwy:
5 mg PO BID
6 mg, SC, once every 21 days
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
---|---|
Determination of the maximum tolerated dose (MTD) of the combination of cabazitaxel and mitoxantrone/prednisone as chemotherapy for patients with metastatic CRPC who have not received prior chemotherapy for metastatic disease.
Ramy czasowe: Participants will be followed for the duration of treatment, an expected average of 4 months.
|
Participants will be followed for the duration of treatment, an expected average of 4 months.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Dose Limiting Toxicity (DLT)
Ramy czasowe: Participants will have AE/Toxicity evaluations every 21 days. Average study participation is approximately 4 months.
|
Number of Grade 3 or greater non-hematologic toxicity recorded.
|
Participants will have AE/Toxicity evaluations every 21 days. Average study participation is approximately 4 months.
|
Reduction in Prostate Specific Antigen (PSA), of the combination of cabazitaxel and mitoxantrone/prednisone in patients with metastatic CRPC who have not received prior chemotherapy for metastatic disease.
Ramy czasowe: Participants will have PSA assessments every 21 days. Average study participation is approximately 4 months.
|
Participants will have PSA assessments every 21 days. Average study participation is approximately 4 months.
|
|
Efficacy of drug combination including objective response rate and duration of response
Ramy czasowe: Participants will be followed for the duration of treatment, an expected average of 4 months.
|
Participants will be followed for the duration of treatment, an expected average of 4 months.
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Krzesło do nauki: Rahul Aggarwal, MD, University of California, San Francisco
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Nowotwory
- Nowotwory układu moczowo-płciowego
- Nowotwory według lokalizacji
- Nowotwory narządów płciowych, mężczyzna
- Choroby prostaty
- Nowotwory prostaty
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Agenty obwodowego układu nerwowego
- Inhibitory enzymów
- Środki przeciwbólowe
- Agenci systemu sensorycznego
- Środki przeciwzapalne
- Środki przeciwnowotworowe
- Glikokortykosteroidy
- Hormony
- Hormony, substytuty hormonów i antagoniści hormonów
- Środki przeciwnowotworowe, hormonalne
- Inhibitory topoizomerazy II
- Inhibitory topoizomerazy
- Prednizon
- Mitoksantron
Inne numery identyfikacyjne badania
- UCSF Protocol No. 11951
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Cabazitaxel
-
Rambam Health Care CampusZakończony
-
University of Alabama at BirminghamSanofiZakończonyNiedrobnokomórkowy rak płuc (NSCLC) | NSCLC z przerzutami | NSCLC stopnia IVStany Zjednoczone
-
Krzysztof MisiukiewiczSanofi; Icahn School of Medicine at Mount SinaiZakończony
-
SanofiZakończonyRak prostaty z przerzutamiIndie
-
SanofiZakończony
-
SanofiZakończony